Published in final edited form as:

Acta Neuropathol. 2008 December ; 116(6): 583–595. doi:10.1007/s00401-008-0449-0.

Inclusion-Body Myositis: Muscle-Fiber Molecular Pathology and Possible Pathogenic Significance of Its Similarity to Alzheimer and Parkinson Disease Brains

Valerie Askanas and W. King Engel

USC Neuromuscular Center, Department of Neurology, University of Southern California Keck School of Medicine, Good Samaritan Hospital, 637 South Lucas Avenue, Los Angeles, CA

Abstract

Sporadic inclusion-body myositis (s-IBM), the most common muscle disease of older persons, is of unknown cause and lacks successful treatment. Here we summarize diagnostic criteria and discuss our current understanding of the steps in the pathogenic cascade. While it is agreed that both degeneration and mononuclear-cell inflammation are components of the s-IBM pathology, how each relates to the pathogenesis remains unsettled. We suggest that the intra-muscle-fiber degenerative component plays the primary role, leading to muscle-fiber destruction and clinical weakness, since anti-inflammatory treatments are not of sustained benefit. We discuss possible treatment strategies aimed toward ameliorating a degenerative component, for example, lithium and resveratrol. Also discussed are the intriguing phenotypic similarities between s-IBM muscle fibers and the brains of Alzheimer and Parkinson diseases, the most common neurodegenerative diseases associated with aging. Similarities include, in the respective tissues, cellular aging, mitochondrial abnormalities, oxidative and endoplasmic reticulum stresses, proteasome inhibition and multiprotein aggregates.

Keywords

inclusion-body myositis; amyloid-beta; multiprotein aggregates; muscle-fiber degeneration; inflammation; endoplasmic-reticulum stress; Alzheimer disease; Parkinson disease; lithium; resveratrol

INTRODUCTION

Sporadic inclusion-body myositis (s-IBM) is the most common muscle disease of older persons, age 55 +. Its course is relentlessly progressive and there is no successful treatment. The s-IBM molecular muscle-fiber phenotype is virtually unique for a muscle disease, in that the pathological abnormalities within muscle fibers bear a number of strong similarities to Alzheimer and Parkinson disease brains (details below). In our opinion, those abnormalities play crucial roles in the s-IBM pathogenesis - they likely contribute importantly to the muscle fiber degeneration and atrophy, which ultimately are responsible for the progressive muscle-fiber destruction to cause the relentlessly progressive clinical weakness.

In this article we present our current views on possible mechanisms leading to the characteristic features of s-IBM muscle fibers. We also present our newest data relevant to our concept that

Correspondence to: Valerie Askanas.

Correspondence/reprints to: Valerie Askanas, MD, PhD USC Neuromuscular Center, Good Samaritan Hospital, 637 S. Lucas Ave Los Angeles, CA 90017-1912 Tel. 213-975-9550; Fax 213-975-9955 E-mail: askanas@usc.edu.

s-IBM is an age-associated disorder. And, we discuss the possible relationship between the degenerative and inflammatory components in s-IBM muscle tissues.

Because s-IBM still remains greatly under-diagnosed, we first present a short summary of the pathological diagnostic criteria that we consider important.

DIAGNOSTIC CRITERIA OF THE s-IBM MUSCLE BIOPSY

1. Light-microscopic histochemistry and immunocytochemistry

To diagnose s-IBM, and to help distinguish it from polymyositis, we suggest that the following stainings be performed on 10µm transverse sections of a fresh-frozen muscle biopsy: 1) Engel trichrome staining [35] (Fig 1A,B), which reveals several to numerous muscle fibers containing one or a few *vacuoles* in a given section, and various degrees of lymphocytic inflammation (with some macrophages). While some of the vacuoles appear rimmed by a trichrome-reddish material (which indicates lipoprotein membranous material [35,36]), often the vacuoles do not have a conspicuous reddish rim and appear “empty” (these must be distinguished from freeze-artefacts). 2) Fluorescence-enhanced Congo-red [6] to detect *β-pleated-sheet amyloid inclusions* (Fig 1C). Multiple or single foci of amyloid, as identified by Congo-red fluorescence visualized through Texas-red filters [6], are evident within about 60%-80% of the s-IBM vacuolated muscle fibers in a given transverse section, rarely within vacuoles but mostly in their non-vacuolated regions (the seemingly “amyloid-negative” fibers may have amyloid foci at other levels of those same fibers). This fluorescence-enhanced Congo-red technique is the best and most sensitive method for highlighting amyloid inclusions, which sometimes are very small or few. Crystal violet metachromasia staining can also show the intra-myofiber amyloid deposits [34], more conveniently but much less precisely. Congo-red visualized in polarized light, a widely-used amyloid-seeking method, is the least precise and most difficult to interpret, and should not be used routinely for s-IBM muscle biopsies. 3) Staining with SMI-31 monoclonal antibody, which recognizes *phosphorylated tau (p-tau)*, in Alzheimer disease (AD) brain and s-IBM muscle [3,53,63], and identifies *squiggly inclusions* containing *p-tau* in s-IBM muscle fibers [3,10] (Fig 1D). If SMI-31 antibody is not available, *ubiquitin immunoreactivity* can be used to identify ubiquitin in both p-tau and Aβ intra-myofiber deposits of s-IBM (Fig.1E) [16,73]. Congo-red fluorescence, SMI-31 and ubiquitin immunoreactivities differentiate s-IBM from polymyositis, which does not have intra-fiber deposits positive with those reactions [10,34]. 4) Immuno-staining for amyloid-beta (Aβ) (Fig.1F) is also useful but it is not required to diagnose s-IBM. There are other light-microscopy aspects of s-IBM muscle biopsies that are characteristic and important, but not diagnostic for s-IBM. Examples are: a) *mitochondrial abnormalities*, which include a) *ragged-red fibers* [37], and b) *cytochrome-c-oxidase (COX) negative muscle fibers* that are more common in s-IBM than expected for the patient's age [64,75, and below]. 2. *Small angular muscle fibers*, which are histochemically dark with the pan-esterase and NADH-tetrazolium-reductase reactions. They are always present and are indistinguishable from those in ordinary denervation diseases. Those atrophic fibers are generally considered indicative of “*recent-denervation*” [36], and probably contribute significantly to the clinical weakness [34].

2. Ultrastructural abnormalities of s-IBM muscle fibers

Very characteristic are *paired helical filaments* (PHFs), often in clusters. They strikingly resemble PHFs of AD brain, being 15-21nm diameter [7,62]. They are present in both vacuolated and non-vacuolated muscle fibers (Fig. 2 A,B) [detailed review in in 4]. s-IBM PHFs typically are immunostained with antibodies against phosphorylated tau by both gold- and peroxidase-immuno-electronmicroscopy (Fig.2 C,D).

The s-IBM vacuolated muscle-fiber cytoplasm, and often cytoplasm of non-vacuolated muscle fibers, also contain A β -immuno-positive: a) collections of 6-10 nm filaments; b) fine flocculomembranous material; and c) amorphous material (Fig. 2 E,F) [2,5]. Only A β , and neither N- nor C - terminal epitopes of *amyloid- β precursor protein (A β PP)*, is present on 6-10 nm amyloid-like filaments [2]. Myelin-like whorls and other lysosomal debris are present in the vacuolated fibers. Ultrastructurally *abnormal mitochondria containing paracrystalline inclusions* are occasionally present, but are not specific for s-IBM muscle fibers.

OUR CURRENT CONCEPTS OF s-IBM PATHOGENESIS

1. Characteristic features of s-IBM muscle-fiber degeneration

We consider s-IBM essentially a degenerative muscle disease: a) occurring within an aged muscle cellular environment; b) associated with intracellular accumulation and aggregation of a number of proteins;c) in conjunction with oxidative and endoplasmic-reticulum stresses; and d) involving abnormal signal transduction and transcription. Those together lead to the IBM-specific muscle-fiber degenerative process.

In addition to muscle-fiber vacuolization and atrophy, degenerating s-IBM muscle fibers are characterized by accumulation of intra-muscle-fiber multiprotein aggregates (“inclusion-bodies”). In a given biopsy cross-section, the aggregates are present mainly in vacuole-free regions of vacuolated muscle-fiber cytoplasm and in cytoplasm of “non-vacuolated” fibers (because muscle fibers are individual cells often centimeters long, they might be vacuolated at another level). The vacuoles themselves usually do not contain the IBM-characteristic inclusions [12]. s-IBM vacuoles are considered autophagic, since they often contain a) lysosomal membranous debris, which is considered an end result of muscle-fiber destruction, and b) increased immunoreactivity of some of the lysosomal enzymes [54a]. The two major types of aggregates/inclusions in s-IBM muscle fibers are: a) the rounded, plaque-like aggregates prominently containing A β immunoreactivity; and b) various-sized delicate, squiggly, linear aggregates containing p-tau, which are paired helical filaments by EM [12, 13]. Both types of aggregates contain proteins that are congophilic, indicating β -pleated-sheet configuration of amyloid [12]. And both also contain other proteins having a propensity to misfold, including α -synuclein and presenilin1 [4,8,12, also below]. Other characteristic features of the s-IBM muscle-fiber phenotype are evidence of proteasome inhibition, endoplasmic reticulum (ER) stress, and the unfolded-protein-response (UPR) [40,68,99, and below]. Accordingly, we consider that s-IBM is a conformational disease of muscle in which unfolding and misfolding of proteins within muscle fibers play a major role in cytotoxicity and in formation of multiprotein-aggregates [11,12]. We recently demonstrated activation of NF- κ B [69], which also provides important insight into the s-IBM pathogenesis (below). We postulate that the *aging cellular milieu* in the s-IBM muscle fiber is important in promoting development of the characteristic progressive vacuolar degeneration and over-expression/accumulation of several potentially toxic proteins that may underlie disease progression (details below). Despite a concurrent over-expression of both putatively protective and damaging proteins and mechanisms [13], the defensive and reparative mechanisms are evidently insufficient because the muscle fibers continue to deteriorate and eventually die. Also contributing to progression might be that -- compared to other myopathies including polymyositis and dermatomyositis -- in s-IBM there is a definite paucity of regenerating muscle fibers [63, and Askana, V and Engel, WK, personal observations].

2. Possible relationship between muscle-fiber degeneration and lymphocytic inflammation in s-IBM muscle biopsies

Also characteristic component of s-IBM muscle biopsies is a lymphocytic inflammation, mainly composed of cytotoxic CD8 cells [reviewed in 28]. A debated but un-resolved issue is

which component, degenerative or inflammatory, is preceding in the s-IBM pathogenesis [13,28,65]. An earlier study reported that in cultured muscle cells, A β induces expression of IL-6 [17], supporting a primary, or possibly aggravating, role of A β in inducing an immune response. Conversely, a recent study reported that cytokine IL-1 β induces A β PP in cultured muscle cells [78], supporting a primary, or perhaps an aggravating, role of inflammation in s-IBM [30]. Another argument given for primacy of the inflammatory component is that s-IBM muscle fibers abundantly express MHC-1, and muscle fibers expressing MHC-1 are invaded by clonally-expanded cytotoxic CD8⁺ lymphocytes [28,29], as also occurs in polymyositis [28,29]. However, MHC-1 expression is also present on regenerating muscle fibers in various other myopathies [29, and Paciello and Askanas, unpublished observations 2005]. Moreover, MHC-1 is strongly expressed on non-regenerating muscle fibers in a) genetic dysferlin deficiency, where it is associated with CD4 rather than CD8 T-lymphocyte response [21], and b) in limb-girdle muscular dystrophy 2-I, where it is accompanied by inflammation [31]. In those two examples, presumably the genetic protein abnormally somehow leads to the MHC-1 expression. While MHC-1 is critical for a muscle fiber to become antigen-presenting, the mechanisms causing MHC-1 expression in s-IBM fibers are not known. There are several possible mechanisms. One is provocation by the acquired dysconfiguration of intra-muscle fiber proteins (see below). Or possibly, MHC-1 expression in s-IBM results from the demonstrated endoplasmic reticulum (ER) stress [68,99, and see below], which additionally might be induced by A β PP that associates with ER chaperones GRP78 and GRP 94 [99]. It has been shown that binding of ER chaperones to some peptides leads to expression of MHC-1, cellular antigen display, and activation of MHC-restricted T-cells [18,85,92]. ER-stress recently has been shown to induce inflammatory and autoimmune responses [91,115]. Very recently, we demonstrated activation of NF- κ B in s-IBM muscle fibers [69] -- since NF- κ B is a known proinflammatory factor [57], such NF- κ B activation might contribute to s-IBM inflammation. Relevant to treating patients, the main consideration in analyzing the s-IBM pathogenesis should focus less on whether inflammatory features are primary or secondary, and more on which of the pathologic abnormalities lead to muscle-fiber degeneration and weakness. It is now well-accepted that despite accumulation and activation of T-cells, s-IBM patients as a group respond poorly to anti-dysimmune treatment, in contrast to polymyositis patients, who have virtually identical immunopathologic abnormalities in their muscle biopsies [13,28,29,34,65]. This suggests that non-inflammatory factors are clinically more important.

We propose that the degenerative component within s-IBM muscle fibers (see details below) is pathogenically more important and is responsible for lack of response to various immune-modulating treatments. Accordingly, therapeutic considerations should focus on reducing detrimental degenerative components (suggestions below).

3. Possible detrimental role of various proteins abnormally accumulated within s-IBM muscle fibers

1) Intra-cellular toxicity of A β PP/A β —We have proposed for several years that increased *intracellular* expression of A β PP and of its proteolytic fragment A β play key upstream, toxic roles in the s-IBM pathogenesis [10,12,13]. Several experimental studies, including the cultured human muscle IBM model, and transgenic mouse models, provide strong evidence for an intracellular toxicity of A β PP/A β in s-IBM [recently reviewed in detail in 13]. Increased A β PP mRNA and abnormal accumulation of both A β PP and A β are identified early in s-IBM abnormal muscle fibers [10,12]. In addition, there are abnormalities of the A β PP processing machinery. BACE1 and BACE2, which are glycosylated transmembrane β -secretases that cleave A β PP at the N-terminal of A β [48,58,82], are increased in s-IBM muscle fibers, where they are accumulated in the form of inclusions co-localizing with A β [100,101]. BACE 1 also co-immunoprecipitates with A β PP in s-IBM muscle [109], suggesting that it may participate in A β PP processing and abnormal generation of the A β there. *Nicastrin* and *presenilins*, which

are components of the *γ-secretase system* that cleaves AβPP at the C-terminal of Aβ, generating either Aβ40 or Aβ42 [reviewed in 83,103], are also strongly overexpressed in s-IBM muscle fibers, where they (i) colocalize with each other and with AβPP [81,102], and (ii) are physically associated with AβPP in both s-IBM and in experimentally AβPP-overexpressing muscle fibers (Vattemi and Askana, unpublished observation 2003). Accordingly, both β- and γ-secretases appear to participate in Aβ production within s-IBM muscle fibers. This probably would not be a problem if the Aβ would be properly disposed of (see below). AβPP/Aβ overexpressed in regenerating muscle fibers in various other muscle diseases does not seem to cause difficulty and is not associated with the s-IBM type of muscle-fiber degeneration [76,101]. Our most recent studies showed that in s-IBM muscle fibers AβPP is phosphorylated [89], and according to others, phosphorylation of AβPP increases its toxicity and assembly into Aβ toxic oligomers [23,56].

Additionally, in s-IBM muscle fibers, there is preferential accumulation of the Aβ42 fragment [97], which is known to be more hydrophobic and more prone to self-association and oligomerization, and as such is much more cytotoxic than Aβ40 [38,42,43,105]. Aβ cytotoxicity is considerably enhanced by its oligomerization. [38,42,43,105]. In s-IBM muscle fibers, all congophilic (*i.e.*, fibrillar, amyloidic) Aβ inclusions contain Aβ42 (Fig.3, and Vattemi and Askana, unpublished), while only some contain both Aβ40 and Aβ42 [97]. There are several other factors acting in s-IBM muscle fibers that might contribute to Aβ production, deposition and oligomerization. These include increased expression and accumulation of: 1) cystatin C (CC), an endogenous cysteine protease inhibitor, which was previously proposed to participate in Aβ deposition within the amyloid plaques AD brain [98]; 2) transglutaminases 1a and 2, which contribute to Aβ aggregation and insolubility by cross-linking Aβ molecules [26], and 3) free cholesterol [50], which increases Aβ production and amyloidogenesis [referenced in 50]. Our recent study [108] demonstrated that in s-IBM biopsied muscle and in AβPP-overexpressing cultured human muscle fibers, αB-crystallin (αBC), which specifically recognizes and stabilizes proteins that have a propensity to aggregate and precipitate [32,84, 113], physically associated with AβPP and Aβ oligomers [108]. Therefore, binding of αBC to Aβ oligomers conceivably might retard and diminish their fibrillization and aggregation into visible non-toxic aggregates, thereby adversely prolonging their existence as toxic oligomers, increasing their cytotoxicity [108]. (Alternatively, that binding of αBC conceivably could detoxify Aβ).

2) Myostatin—Myostatin (MSTN) is a secreted protein, considered to be a negative regulator of muscle growth during development and of muscle mass during adulthood [reviewed in 51]. In biopsied s-IBM muscle fibers, MSTN precursor protein (MSTN-PP) and MSTN dimer were significantly increased; and MSTN-PP was physically associated with AβPP, and co-localized with Aβ by light- and electronmicroscopic immunocytochemistry [107]. Moreover, AβPP-overexpression into cultured normal human muscle fibers increased MSTN-PP expression, and subsequent experimental inhibition of proteasome caused co-accumulation of both MSTN-PP/MSTN and AβPP/Aβ within aggresomes, and their physical association was evident by immunoprecipitation [110]. We proposed that AβPP binding to MSTN-PP causes its posttranslational modification that lessens its degradation and traffic, resulting in MSTN-PP accumulation. Of particular interest are our recent studies demonstrating that in cultured human muscle fibers MSTN-PP mRNA and MSTN protein are significantly increased by NF-κB activation caused by experimentally-induced ER-stress [69]. The same mechanisms might contribute to the increase of MSTN in s-IBM muscle fibers, because: a) ER-stress is an important component of the s-IBM pathogenesis; and b) the activity of NF-κβ is increased in s-IBM muscle fibers [69]. Fig. 4 illustrates our proposed mechanisms leading to MSTN increase and accumulation in s-IBM muscle fibers.

3) α -Synuclein (α -syn)—Abnormal expression of α -syn occurring spontaneously in brains of various neurodegenerative disorders has been associated with, and possibly causative of, oxidative stress, impaired proteasome function, and mitochondrial abnormalities [20,27,45, 59,94]. We have shown a) that α -syn is accumulated in s-IBM muscle fibers [4], and b) that its 22kDa O-glycosylated form is more expressed than its native 16kDa form [72]. The 22kDa form, but not the native 16kDa form, was shown by others to be a target of ubiquitination by parkin [81]. The preferential increase of the 22 kDa O-glycosylated form of α -syn in s-IBM muscle fibers might be due to the proteasome inhibition we previously demonstrated in them [40, and below].

Because oxidative- and nitric-oxide-induced stress, and mitochondrial abnormalities, are also aspects of the s-IBM muscle-fiber pathology [reviewed in 12,13], a putative toxicity of α -syn, in addition to the cytotoxicity of A β and MSTN, may contribute to the muscle-fiber degeneration.

4) Parkin—This is an E3-ubiquitin ligase that ubiquitinates α -syn [77]. Parkin is increased in s-IBM muscle fibers, where it accumulates in the form of aggregates or aggresomes [72]. In brains of sporadic Parkinson disease patients, parkin and α -syn accumulate in Lewy bodies, which are considered aggresomes [77]. Parkin, in addition to ubiquitinating several proteins, also protects cells against toxicity induced by α -syn, ER and other stresses, perhaps by helping to aggregate toxic α -syn oligomers and promote their degradation [49,93]. Accordingly, we propose that increase of parkin in s-IBM muscle fibers is their attempt to protect themselves against toxicity induced by α -syn, ER and other stresses existing within themselves. However, the 2.7-fold increase of parkin in s-IBM muscle fibers might not be sufficient to overcome a 6-fold increase of α -syn [72], or to protect against other continuing stresses. Accordingly, relative insufficiency of parkin could worsen the course of s-IBM. If so, manipulations toward increasing parkin might clinically benefit s-IBM muscle.

4. Other important intracellular abnormalities in s-IBM muscle fibers

1) Decreased deacetylase activity of SIRT1—SIRT1 belongs to the mammalian sirtuin family of NAD⁺-dependent histone deacetylases (HDACs) [44,61,96,111]. Targets known to be deacetylated by SIRT1 include histone 4 (H4), NF- κ B, and p53 [44,61,96,111]. Through its deacetylase activity, SIRT1 is considered to control cellular metabolic homeostasis, and to play an important role in the regulation of gene expression, cell proliferation, differentiation, survival and senescence [44,61,96,111].

SIRT1 activation has been considered to play a crucial role in the calorie-restriction (CR)-induced longevity in several species [61].

In addition, SIRT1 activation has been proposed to play a role in neuroprotection. For example, in an Alzheimer-disease (AD) mouse model, increase of neuronal SIRT1 and its activation were reported to underlie the calorie-restriction prevention of A β -related AD-like neuropathology [74]. In various cell lines, increase of SIRT1 or its activation was reported to protect against A β toxicity by either decreasing the amount of A β by activating α -secretase [74], or by inhibiting NF- κ B activation and its subsequent disturbance of signaling [24].

Our most recent studies have shown that, as compared to age-matched controls, in homogenates of s-IBM muscle fibers SIRT1 activity and deacetylation of SIRT1 targets NF- κ B, H4, and p53 were significantly decreased despite increased SIRT1 protein expression [67]. Within isolated s-IBM muscle nuclei, there was decreased SIRT1 deacetylation activity accompanied by decreased SIRT1 protein expression in them [67]. Since increased acetylation (or decreased deacetylation) of NF- κ B leads to its increased activity [112], decreased SIRT1 deacetylase

activity might be directly responsible for the presumably-detrimental NF- κ B activation in s-IBM muscle fibers.

Our study provides, to our knowledge, the first demonstration of decreased SIRT1 deacetylase activity in any human muscle disease, *viz.*, s-IBM, which is associated with aging. In well-differentiated cultured human muscle fibers, experimentally-induced ER-stress decreased SIRT1 activity and consequently increased NF κ B acetylation (activation) [67]. Accordingly, in s-IBM muscle fibers, inadequate activity of SIRT1 may be detrimental by increasing NF- κ B activation, and thereby contributing to the abnormal accumulation of A β and increased MSTN. Our proposed important consequences of decreased SIRT1 activity in s-IBM muscle fibers are illustrated in Fig.5.

If correct, improving SIRT1 action by treatment with known SIRT1 activators might benefit s-IBM patients (see below).

2) Proteasome inhibition and aggresomes—The 26S *proteasome*, an about 700 kDa multi-subunit protease complex present in the cytoplasm and nuclei of eukaryotic cells, has a major role in degrading normal and abnormal proteins through a ubiquitin-mediated process [104]. We have reported significant inhibition of the 26S proteasome function in a) s-IBM muscle fibers, and b) cultured human muscle fibers experimentally overexpressing A β /A β PP [40]. *Aggresomes*, which form when the proteasome is inhibited [referenced in 40], are also part of the s-IBM muscle-fiber phenotype [40] -- they were induced in cultured human muscle fibers by overexpressing A β PP $\pm$ proteasome inhibition [40].

In addition to increased A β /A β PP, other factors -- such as an aging muscle-fiber environment, protein over-crowding, oxidative stress, and accumulated p-tau, α -synuclein, and UBB⁺¹ (referenced in [40] and below) -- might contribute to proteasome inhibition in s-IBM muscle fibers, resulting in accumulation of aggregated misfolded proteins into aggresomes. Furthermore, the unfolded/misfolded proteins might, in the putatively susceptible s-IBM patients, elicit expression and presentation of MHC-1 by the muscle fiber, and consequently induce a secondary CD8 T-cell response (see above).

3) Molecular misreading and accumulation of mutated ubiquitin (UBB⁺¹)

—“Molecular misreading” involves acquired, non-DNA-encoded dinucleotide deletions occurring within mRNAs, resulting in production of potentially toxic mutant proteins [recently reviewed in 95]. The aberrant transcripts are formed as a result of dinucleotide loss (Δ GA, Δ GU) during or after transcription, and they can be translated from the deletion onward into the +1 reading-frame to produce abnormal proteins, *e.g.* mutant ubiquitin, termed UBB⁺¹. UBB⁺¹ protein was shown accumulated in the dystrophic neurites as a component of neuritic plaques, and in neurofibrillary tangles of Alzheimer disease (AD) brain [95], as well as in brains of other neurodegenerative disorders in which inhibition of the proteasome has been proposed to play a pathogenic role [95]. UBB⁺¹ itself can become ubiquitinated, and then that form can inhibit the proteasome [95].

In s-IBM muscle fibers, UBB⁺¹ was shown accumulated in the form of aggregates, providing the first demonstration that molecular misreading can occur in diseased human muscle [41]. We suggested that the aging cellular environment of s-IBM muscle fibers, combined with factors such as oxidative stress and perhaps other detrimental molecular events, leads to abnormal production and accumulation of UBB⁺¹ [41]. Moreover, a high level of UBB⁺¹ inhibits the 26S proteasome [95], and this mechanism might contribute to proteasome inhibition in s-IBM muscle fibers.

4) Endoplasmic reticulum stress (ERS) and the unfolded protein response (UPR)

—The ER is an intracellular compartment having a critical role in the processing, folding and exporting of newly synthesized proteins into the secretory pathway [reviewed in 91,114,115]. In the ER, molecular chaperones are required to assure proper folding of unfolded or misfolded proteins [91,114,115]. Unfolded proteins accumulating in the ER cause ER stress [91,114,115]. This elicits the UPR, a functional mechanism by which a cell attempts to protect itself against ERS [91,114,115]. In s-IBM muscle fibers, we have previously reported evidence of ER stress and the UPR [68,99]. Recently, we demonstrated that in cultured normal human muscle fibers experimentally-produced ER stress a) induces MSTN through an NF- κ B related mechanism, and b) decreases SIRT1 deacetylase activity [see above and 67,69]. Accordingly, ER stress may importantly contribute to the s-IBM pathogenesis.

5) Mitochondrial abnormalities—These include: a) ragged-red fibers [37], b) cytochrome-c-oxidase (COX) negative muscle fibers, and c) multiple mitochondrial DNA deletions [reviewed in 64,70,71]. These are more common in s-IBM muscle than expected for the patient's age [71,75]. Our newest studies confirmed that COX-negative muscle fibers are significantly increased in s-IBM muscle biopsies and, although the COX-negative fibers are 90% Type-II, there is more involvement of Type-I fibers than in controls [87]. Our morphologically-determined total percent of “COX-negative fibers” on transverse sections probably greatly underestimates their actual number because on longitudinal view the regions of COX-negativity are segmentally multifocal along the fibers [71; our unpublished observation]. Although we previously showed in our IBM-model that excessive A β PP and A β contribute to the mitochondrial abnormalities [15] (a concept now supported by studies in other systems, especially as putatively related to AD and Parkinson's brain [1,45,46 and referenced in 89]), our recent studies showed that COX-negative fibers do not preferentially contain aggregated A β and p-tau [87] and, as also recently reported [22], they do not correlate with foci of mononuclear inflammatory cells [87]. Accordingly, other yet-unknown mechanisms seem to be causing the prominent COX-negativity in s-IBM muscle fibers. Possibilities include: toxic unaggregated oligomers of A β , α -syn, or other proteins; and factors resulting from oxidative or ER stresses. Discovery of their cause could facilitate developing treatment strategies. The mitochondrial abnormalities presumably contribute to the muscle-fiber malfunction and degeneration.

In the seemingly otherwise-intact muscle fibers, regions of COX-negativity cannot make ATP via oxidative-phosphorylation -- those presumably weakened regions must be surviving on ATP diffusing from adjacent COX-positive regions or produced by anaerobic glycolysis.

6. DJ-1—The Parkinson-disease-related DJ-1 is a ubiquitously-expressed protein of the ThiJ/PfpI/DJ1 superfamily [reviewed in 19,25,86 and referenced in 90]. We recently reported that DJ-1 is increased in s-IBM muscle fibers, where it is a) highly oxidized and b) abnormally accumulated in muscle-fiber mitochondria [90]. Mutations in the DJ-1 gene that prevent expression of DJ-1 protein are a cause of early-onset autosomal-recessive Parkinson disease (PD) [19,25,86]. In sporadic AD and PD brains, DJ-1 was reported to be increased and highly oxidized [25]. Although its precise functions are not yet known, DJ-1 has been proposed to act as an antioxidant [86; and referenced in 90] and be an important mitochondrial protective agent [referenced in 90]. Increased oxidation of DJ-1 itself was proposed to decrease its anti-oxidant activity [86, and referenced in 90]. We suggest that in s-IBM muscle fibers the increased DJ-1 may be attempting to mitigate mitochondrial and oxidative damage, but its being excessively oxidized may render it ineffective [90].

POSSIBLE TREATMENT AVENUES FOR s-IBM

Based on our studies, we propose that the most important general approach to developing treatment for s-IBM patients or to prevent progression of the disease is to stop deterioration and atrophy of the muscle fibers. The treatment approaches might be multifactorial, aiming toward various detrimental factors described above. Some approaches, based on our experimental IBM culture models, appear promising. For example, our most recent studies demonstrated the following:

1. Resveratrol

Treatment with resveratrol of ER-stress-induced cultured human muscle fibers (ER-stress+ IBM-culture-model) significantly decreased in them myostatin mRNA and protein, and was associated NF- κ B de-acetylation (de-activation) [66]. Previously, resveratrol was shown to decrease A β and diminish AD neuropathology in AD mouse models [reviewed in 27a]. Resveratrol (trans-3, 4', 5-trihydroxystilbene), is an antioxidant polyphenol and a potent activator of SIRT1 [reviewed in 27]. Accordingly, resveratrol, and/or other small molecules that activate SIRT1, activity of which is decreased in s-IBM muscle [67], might be beneficial in treating s-IBM patients. Recently, SIRT1 activity has been reported to increase autophagy [56a]. Although the exact role of autophagy in s-IBM awaits further studies, resveratrol possibly could also benefit s-IBM patients through induction of autophagy.

2. Lithium

Lithium has previously been shown to diminish tau and A β pathologies in various experimental models of AD [reviewed in 33], but its clinical efficacy in treating AD patients is not established. In a transgenic mouse model whose skeletal muscle bears some aspects of IBM muscle fibers, lithium was reported to decrease tau phosphorylation through decreasing activity of GSK-3 β [52a].

Recently, we have shown that treatment of A β PP-overexpressing cultured human muscle fibers (A β PP+ culture-IBM-model) with lithium significantly decreased total A β PP, phosphorylated A β PP, and A β oligomers [88]. In addition, lithium significantly increased the inactive form of GSK-3 β and increased expression of an autophagosome marker LC3-II [88]. Accordingly, treating of s-IBM patients with lithium possibly could be beneficial.

3. Other possible treatments

Other approaches may involve the following. 1) Stopping hyper-phosphorylation of tau, which leads to its self-aggregation into PHFs, or blocking the aggregation process itself (and blocking any hypothetical binding of hyper-phosphorylated tau to normal cellular components). 2) Diminishing adverse effects of intra-muscle fiber cholesterol. However, the use of statins is of uncertain benefit and potentially myotoxic. 3) Reducing oxidative stress with various antioxidants. 4) Protecting mitochondria, especially ones not yet affected, perhaps with very-high-dose Coenzyme Q10 and L-carnitine (neither of proven efficacy), and with better protective molecules as they are developed. Greater understanding of molecular mechanisms associated with human muscle-fiber aging could provide new avenues toward s-IBM therapy.

INTRIGUING SIMILARITIES OF THE s-IBM MUSCLE FIBER PHENOTYPE TO THOSE OF BRAINS OF ALZHEIMER AND PARKINSON DISEASES

Similarities to the Alzheimer-disease brain include accumulation of A β , phosphorylated tau (p-tau) and more than 15 other Alzheimer-characteristic proteins [8,10,12,13]. For years it was considered that the *extracellular* A β is exerting the main toxic, detrimental role in AD brain [79,80]. However, more than a decade ago we proposed that our demonstrated *intracellular*

increase and toxicity of A β PP and of its proteolytic fragment A β play the key cytotoxic role in the s-IBM pathogenic cascade [14,15] - furthermore we postulated that the same *intra* cellular toxicity might be occurring in the AD pathogenesis [9]. This proposal regarding AD now seems to be gaining momentum, because more and more AD researchers discuss the possible importance of *intracellular* A β accumulation and toxicity in the AD pathogenesis [reviewed in 42,55]

Interestingly, there are also phenotypic similarities of s-IBM muscle fibers to the Parkinson disease brain, such as accumulation of α -syn, parkin and abnormalities of DJ-1, the latter also being present in AD brain [25]. These similarities suggest that the degenerative muscle and the brain diseases may share certain pathogenic steps - and knowledge of one disease might help elucidate the causes and treatments of the others. IBM, AD, and PD, including sporadic and hereditary forms of each, are all *multifactorial* and *polygenetic*. The respective cascade of events in each leading to their similar pathologic aspects is not well understood -- cellular aging, protein misfolding, aggregation, proteasome inhibition, and mitochondrial abnormalities, as well as oxidative and ER-stress have been proposed to be contributing in s-IBM, AD and PD [above, and reviewed in 1,39,47,52,54,60,70,106]. Yet each disease category remains tissue- and region-specific, involving postmitotic-muscle fibers or postmitotic-neurons, thereby indicating that the mechanism of *cellular-targeting* is different in IBM, AD and PD. The tissue affected, muscle versus brain, may be influenced by: 1) etiologic agent (? a virus); 2) previous exposure to an environmental factor(s); 3) subtle differences of deficiency or toxicity factors; and 4) the patient's genetic background (the cellular microclimate). Easier availability of s-IBM patients' muscle biopsies, as compared to brain tissue, and the possibility of producing IBM experimental models by utilizing cultured human muscle fibers (which are the cells actually affected in the s-IBM disease process), might provide better understanding of some pathogenic aspects, not only related to s-IBM, but also to AD and PD, and facilitate development of treatments.

Acknowledgement

Supported in parts by grants (to VA) from the National Institutes of Health (NS34103 and AG16768 Merit Award), the Muscular Dystrophy Association, The Myositis Association (to VA) and the Helen Lewis Research Fund.

REFERENCES

1. Abou-Sleiman PM, Muqit MMK, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. *Nature Rev Neurosci* 2006;7:207–219. [PubMed: 16495942]
2. Askanas V, Alvarez RB, Engel WK. β -amyloid precursor epitopes in muscle fibers of inclusion body myositis. *Ann Neurol* 1993;34:551–560. [PubMed: 7692809]
3. Askanas V, Alvarez RB, Mirabella M, Engel WK. Use of antineurofilament antibody to identify paired-helical filaments in inclusion-body myositis. *Ann Neurol* 1996;39:389–391. [PubMed: 8602760]
4. Askanas V, Engel WK, Alvarez RB, McFerrin J, Broccolini A. Novel immunolocalization of α -synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions. *J Neuropathol Exp Neurol* 2000;59:592–598. [PubMed: 10901230]
5. Askanas V, Engel WK, Alvarez RB. Light- and electronmicroscopic localization of β -amyloid protein in muscle biopsies of patients with inclusion-body myositis. *Am J Pathol* 1992;141:31–36. [PubMed: 1321564]
6. Askanas V, Engel WK, Alvarez RB. Enhanced detection of Congo-red positive amyloid deposits in muscle fibers of inclusion-body myositis and brain of Alzheimer's disease using fluorescence technique. *Neurology* 1993;43:1265–1267. [PubMed: 8170582]
7. Askanas V, Engel WK, Bilak M, Alvarez RB, Selkoe DJ. Twisted tubulofilaments of inclusion-body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. *Am J Pathol* 1994;144:177–187. [PubMed: 8291607]

8. Askanas V, Engel WK, Yang C-C, Lee M-Y, Wisniewski G. Light and electron microscopic immunolocalization of Presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy. *Am J Pathol* 1998;152:889–895. [PubMed: 9546349]
9. Askanas V, Engel WK. Does overexpression of BetaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease. *Am J Pathol* 1998;153:1673–1677. [PubMed: 9846956]
10. Askanas V, Engel WK. Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. *J Neuropathol Exp Neurol* 2001;60:1–14. [PubMed: 11202170]
11. Askanas V, Engel WK. Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid- β misfolded proteins, predisposing genes, and aging. *Curr Opin Rheumatol* 2003;15:737–744. [PubMed: 14569203]
12. Askanas V, Engel WK. Inclusion-body myositis: A myodegenerative conformational disorder associated with A β , protein-misfolding, and proteasome inhibition. *Neurology* 2006;66:S39–48. [PubMed: 16432144]
13. Askanas V, Engel WK. Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. *Curr Opin Rheumatol* 2007;19:550–559. [PubMed: 17917534]
14. Askanas V, McFerrin J, Alvarez RB, Baque S, Engel WK. β APP gene transfer into cultured human muscle induces inclusion-body myositis aspects. *NeuroReport* 1997;8:2155–2158. [PubMed: 9243602]
15. Askanas V, McFerrin J, Baque S, Alvarez RB, Sarkozi E, Engel WK. Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. *Proc Natl Acad Sci USA* 1996;93:1314–1319. [PubMed: 8577761]
16. Askanas V, Serdaroglu P, Engel WK, Alvarez RB. Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light-microscopic distinction from polymyositis. *Neurology* 1992;42:460–461. [PubMed: 1310532]
17. Baron P, Galimberti D, Meda L, Scarpini E, Conti G, Cogiamanian F, et al. Production of IL-6 by human myoblasts stimulated with A β : relevance in the pathogenesis of IBM. *Neurology* 2001;57:1561–1565. [PubMed: 11706091]
18. Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S, et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. *J Exp Med* 1997;186:1315–1322. [PubMed: 9334371]
19. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. *Science* 2003;299:256–259. [PubMed: 12446870]
20. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. *Nat Med* 2004;10:S2–9. [PubMed: 15272266]
21. Brunn A, Schröder R, Deckert M. The inflammatory reaction pattern distinguishes primary dysferlinopathies from idiopathic inflammatory myopathies: an important role for the membrane attack complex. *Acta Neuropathol* 2006;112:325–332. [PubMed: 16862423]
22. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. *Neurology* 2008;70:418–424. [PubMed: 17881720]
23. Chang KA, Kim HS, Ha TY, Ha JW, Shin KY, Jeong YH, et al. Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. *Mol Cell Biol* 2006;26:4327–4338. [PubMed: 16705182]
24. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. *J Biol Chem* 2005;280:40364–40374. [PubMed: 16183991]
25. Choi J, Sullards MC, Olzmann JA, Rees HD, Weintraub ST, Bostwick DE, et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. *J Biol Chem* 2006;281:10816–24. [PubMed: 16517609]
26. Choi Y-C, Park GT, Kim T-S, Sunwoo IN, Steinert PM, Kim SY. Sporadic inclusion body myositis correlates with increased expression and cross-linking by transglutaminases 1 and 2. *J Biol Chem* 2000;275:8703–8710. [PubMed: 10722712]

27. Cookson MR. The biochemistry of Parkinson's disease. *Annu Rev Biochem* 2005;74:29–52. [PubMed: 15952880]
- 27a. Cucciolla V, Borriello A, Oliva A, Galletti P, Zappia V, Ragione FD. Resveratrol from basic science to the clinic. *Cell Cycle* 2007;6:2495–2510. [PubMed: 17726376]
28. Dalakas MC. Inflammatory, immune, and viral aspects of inclusion-body myositis. *Neurology* 2006;66:S33–38. [PubMed: 16432143]
29. Dalakas MC. Sporadic inclusion body myositis - - diagnosis, pathogenesis and therapeutic strategies. *Nat Clin Pract Neurol* 2006;2:437–447. [PubMed: 16932602]
30. Dalakas MC. Interplay between inflammation and degeneration: using inclusion body myositis to study “neuroinflammation”. *Ann Neurol* 2008;64:1–3. [PubMed: 18626972]
31. Darin N, Krokmark AK, Ahlander AC, Moslemi AR, Oldfors A, Tulinius M. Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2. *Eur J Paediatr Neurol* 2007;11:353–57. [PubMed: 17446099]
32. Derham BK, Harding JJ. Alpha-crystallin as a molecular chaperone. *Prog Retin Eye Res* 1999;18:463–509. [PubMed: 10217480]
33. Engel T, Goñi-Oliver P, Gomez de Barreda E, Lucas JJ, Hernandez F, Avila J. Lithium, a potential protective drug in Alzheimer's disease. *Neurodegenerative Dis* 2008;5:247–249.
34. Engel WK, Askanas V. Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. *Neurology* 2006;66:S20–29. [PubMed: 16432141]
35. Engel WK, Cunningham GG. Rapid examination of muscle tissue - an improved trichrome method for fresh-frozen biopsy sections. *Neurology* 1963;13:919–923. [PubMed: 14079951]
36. Engel WK. The essentiality of histo- and cytochemical studies of skeletal muscle in the investigation of neuromuscular disease. *Neurology* 1962;12:778–794.
37. Engel WK. “Ragged-red fibers” in ophthalmoplegia syndromes and their differential diagnosis. Abstracts 2nd Intl Cong Muscle Diseases, Perth, Australia. *Excerpta Med Inter Cong Series* 1971;237:28.
38. Ferreira ST, Vieira MNN, De Felice FG. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. *IUBMB Life* 2007;59:332–345. [PubMed: 17505973]
39. Forloni G, Terreni L, Bertani H, Fogliarino S, Ivernizzi R, Assini A, et al. Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. *Neurobiol Aging* 2002;23:957–976. [PubMed: 12392798]
40. Fratta P, Engel WK, McFerrin J, Davies KJA, Lin SW, Askanas V. Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. *Am J Pathol* 2005;167:517–526. [PubMed: 16049336]
41. Fratta P, Engel WK, van Leeuwen FW, Hol EM, Vattermi G, Askanas V. Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers. *Neurology* 2004;63:1114–1117. [PubMed: 15452314]
42. Glabe C. Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. *J Mol Neurosci* 2001;17:137–145. [PubMed: 11816787]
43. Glabe C, Kaye R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. *Neurology* 2006;66:S74–78. [PubMed: 16432151]
44. Haigis MC, Guarente LP. Mammalian sirtuins -- emerging roles in physiology, aging, and calorie restriction. *Genes Dev* 2006;20:2913–2921. [PubMed: 17079682]
45. Hashimoto M, Rockenstein E, Crews L, Masliah E. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. *Neuromolecular Med* 2003;4:21–36. [PubMed: 14528050]
46. Hong WK, Han EH, Kim DG, Ahn JY, Park JS, Han BG. Amyloid-beta-peptide reduces the expression level of mitochondrial cytochrome oxidase subunits. *Neurochem Res* 2007;32:1483–1488. [PubMed: 17514422]
47. Hoozemans JJM, van Haastert ES, Eikelenboom P, de Vos RAI, Rozemuller JM, Scheper W. Activation of the unfolded protein response in Parkinson's disease. *Biochem Biophys Res Commun* 2007;354:707–711. [PubMed: 17254549]

48. Hussain I, Powell DJ, Howlett DR, Chapman GA, Gilmour L, Murdock PR, et al. ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. *Mol Cell Neurosci* 2000;16:609–619. [PubMed: 11083922]
49. Imai Y, Soda M, Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. *J Biol Chem* 2000;275:35661–35664. [PubMed: 10973942]
50. Jaworska-Wilczynska M, Wilczynski GM, Engel WK, Strickland DK, Weisgraber KH, Askanas V. Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle. *Neurology* 2002;58:438–445. [PubMed: 11839845]
51. Joulia-Ekaza D, Cabello G. Myostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects. *Exp Cell Res* 2006;312:2401–2414. [PubMed: 16793037]
52. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer's disease. *J Neurochem* 2000;75:436–439. [PubMed: 10854289]
- 52a. Kitazawa M, Trinh DN, LaFerla FM. Inflammation induces tau pathology in inclusion-body myositis model via glycogen synthase kinase-3 β . *Ann Neurol* 2008;64:15–24. [PubMed: 18318434]
53. Ksiezak-Reding H, Dickson DW, Davies P, Yen SH. Recognition of tau epitopes by antineurofilament antibodies that bind to Alzheimer neurofibrillary tangles. *Proc Natl Acad Sci USA* 1987;84:3410–3414. [PubMed: 2437579]
54. Kudo T, Katayama T, Imaizumi K, Yasuda Y, Yatera M, Okochi M, et al. The unfolded protein response is involved in the pathology of Alzheimer's disease. *Ann N Y Acad Sci* 2002;977:349–355. [PubMed: 12480772]
- 54a. Kumamoto T, Ueyama H, Tsumura H, Toyoshima I, Tsuda T. Expression of lysosomelated proteins and genes in the skeletal muscles of inclusion-body myositis. *Acta Neuropathol* 2004;107:59–65. [PubMed: 14513262]
55. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. *Nat Rev Neurosci* 2007;8:499–509. [PubMed: 17551515]
56. Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, et al. APP processing is regulated by cytoplasmic phosphorylation. *J Cell Biol* 2003;163:83–95. [PubMed: 14557249]
- 56a. Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, Bruns NE, et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. *Proc Natl Acad Sci USA* 2008;105:3374–3379. [PubMed: 18296641]
57. Li H, Malhotra S, Kumar A. Nuclear factor-kappa B signaling in skeletal muscle atrophy. *J Mol Med* 2008;86:1113–26. [PubMed: 18574572]
58. Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. *Proc Natl Acad Sci USA* 2000;97:1456–1460. [PubMed: 10677483]
59. Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB, et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. *J Bio Chem* 2004;279:12924–12934. [PubMed: 14711827]
60. Matus S, Lisbona F, Torres M, Leon C, Thielen P, Hetz C. The stress rheostat: an interplay between the unfolded protein response (UPR) and autophagy in neurodegeneration. *Curr Mol Med* 2008;8:157–172. [PubMed: 18473817]
61. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. *Biochem J* 2007;404:1–13. [PubMed: 17447894]
62. Mirabella M, Alvarez RB, Bilak M, Engel WK, Askanas V. Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies. *J Neuropathol Exp Neurol* 1996;55:774–786. [PubMed: 8965093]
63. Morosetti R, Mirabella M, Gliubuzzi C, Broccolini A, De Angelis L, Tagliafico E. MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. *Proc Natl Acad Sci U.S.A* 2007;103:16995–17000. [PubMed: 17077152]
64. Moslemi AR, Lindberg C, Oldfors A. Analysis of multiple mitochondrial DNA deletions in inclusion body myositis. *Hum Mutat* 1997;10:381–386. [PubMed: 9375854]
65. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. *Lancet Neurol* 2007;6:620–631. [PubMed: 17582362]
66. Nogalska A, D'Agostino C, Engel WK, Askanas V. Resveratrol, a polyphenol found in red wine, reduces NFkB-activation and myostatin in endoplasmic-reticulum-stress (ERS) - provoked cultured

- human muscle fibers (CHMFs): relevance to treatment of sporadic inclusion-body myositis (s-IBM). *Ann Neurol* 2008;64:S9.
67. Nogalska A, D'Agostino C, Engel WK, Davies KJ, Askanas V. Decreased SIRT1 deacetylase activity in sporadic inclusion-body myositis. *Neurobiol Aging*. 2008doi:10.1016/j.neurobiolaging.2008.08.21
68. Nogalska A, Engel WK, McFerrin J, Kokame K, Komano H, Askanas V. Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in sporadic inclusion-body myositis and in endoplasmic reticulum stress-induced cultured human muscle fibers. *J Neurochem* 2006;96:1491–1499. [PubMed: 16441512]
69. Nogalska A, Wojcik S, Engel WK, McFerrin J, Askanas V. Endoplasmic reticulum stress induces myostatin precursor protein and NF-kappaB in cultured human muscle fibers: relevance to inclusion body myositis. *Exp Neurol* 2007;204:610–618. [PubMed: 17261282]
70. Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson's disease. *Mov Disord* 2006;21:1806–1823. [PubMed: 16972273]
71. Oldfors A, Moslemi AR, Jonasson L, Ohlsson M, Kollberg G, Lindberg C. Mitochondrial abnormalities in inclusion-body myositis. *Neurology* 2006;66:S49–55. [PubMed: 16432145]
72. Paciello O, Wojcik S, Engel WK, McFerrin J, Askanas V. Parkin and its association with α -synuclein and A β PP in inclusion-body myositis and A β PP over-expressing cultured human muscle fibers. *Acta Myol* 2006;25:13–22. [PubMed: 17039976]
73. Prayson RA, Cohen ML. Ubiquitin immunostaining and inclusion-body myositis: study of 30 patients with inclusion body myositis. *Human Pathol* 1997;28:887–892. [PubMed: 9269823]
74. Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. *J Biol Chem* 2006;281:21745–21754. [PubMed: 16751189]
75. Santorelli FM, Sciacco M, Tanji K, Shanske S, Vu TH, Golzi V, et al. Multiple mitochondrial DNA deletions in sporadic inclusion-body myositis: a study of 56 patients. *Ann Neurol* 1996;39:789–795. [PubMed: 8651651]
76. Sarkozi E, Askanas V, Johnson SA, McFerrin J, Engel WK. Expression of β -amyloid precursor protein gene is developmentally regulated in human muscle fibers in vivo and in vitro. *Exp Neurology* 1994;128:27–33.
77. Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. *Am J Pathol* 2002;160:1655–1667. [PubMed: 12000718]
78. Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC. Interrelation of inflammatory and APP in sIBM: IL-1 β induces accumulation of β -amyloid in skeletal muscle. *Brain* 2008;131:1228–1240. [PubMed: 18420712]
79. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. *Physiol Rev* 2001;81:741–766. [PubMed: 11274343]
80. Selkoe DJ. Aging, amyloid, and Alzheimer's disease: a perspective in honor of Carl Cotman. *Neurochem Res* 2003;28:1705–1713. [PubMed: 14584824]
81. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. *Science* 2001;293:263–269. [PubMed: 11431533]
82. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. *Nature* 1999;402:537–540. [PubMed: 10591214]
83. Sisodia S, George-Hyslop PH. Gamma-secretase, Notch, Abeta, and Alzheimer's disease: where do the presenilins fit in? *Nat Rev Neurosci* 2002;3:281–290. [PubMed: 11967558]
84. Stege GJ, Renkawek K, Overkamp PS, Verschuure P, van Rijk AF, Reijnen-Aalbers A, et al. The molecular chaperone alphaB-crystallin enhances amyloid beta neurotoxicity. *Biochem Biophys Res Commun* 1999;262:152–156. [PubMed: 10448084]
85. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. *Science* 1995;269:1585–1588. [PubMed: 7545313]

86. Taira T, Saito YY, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. *EMBO Rep* 2004;5:213–218. [PubMed: 14749723]
87. Terracciano C, Engel WK, Askanas V. In sporadic inclusion-body myositis (s-IBM) muscle biopsies, cytochrome oxidase (COX) negative muscle fibers do not correlate with either inflammation or with aggregates containing amyloid- β ($A\beta$) or phosphorylated tau (p-tau). *Neurology* 2008;70:A304.
88. Terracciano C, Nogalska A, Engel WK, Askanas V. Lithium exerts a beneficial effect on amyloid- β precursor protein ($A\beta$ PP)-overexpressing cultured human muscle fibers (CHMFs). *Ann Neurol* 2008;64:S12.
89. Terracciano C, Nogalska A, Engel WK, Askanas V. Novel demonstration of phosphorylated amyloid- β precursor protein ($A\beta$ PP) in sporadic inclusion-body myositis (s-IBM) muscle fibers. *Neurology* 2008;70:A304.
90. Terracciano C, Nogalska A, Engel WK, Wojcik S, Askanas V. In inclusion-body myositis muscle fibers, Parkinson-associated DJ-1 is increased and oxidized. *Free Radic Biol Med* 2008;45:773–779. [PubMed: 18601999]
91. Todd DJ, Lee AH, Glimcher LH. The endoplasmic reticulum stress response in immunity and autoimmunity. *Nat Rev Immunol* 2008;8:663–674. [PubMed: 18670423]
92. Triantafilou M, Fradelizi D, Triantafilou K. Major histocompatibility class one molecule associates with glucose regulated protein (GRP) 78 on the cell surface. *Human Immunol* 2001;62:764–770. [PubMed: 11476899]
93. Tsai YC, Fishman PS, Thakor NV, Oyler GA. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. *J Biol Chem* 2003;278:22044–22055. [PubMed: 12676955]
94. Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, et al. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. *PLoS ONE* 2008;3:e3135. [PubMed: 18769546]
95. van Leeuwen FW, Hol EM, Fischer DF. Frameshift proteins in Alzheimer's disease and in other conformational disorders: time for the ubiquitin-proteasome system. *J Alzheimers Dis* 2006;9:319–325. [PubMed: 16914870]
96. Vaquero A, Sternglanz R, Reinberg D. NAD⁺-dependent deacetylation of H4 lysine 16 by class III HDACs. *Oncogene* 2007;26:5505–5520. [PubMed: 17694090]
97. Vattemi G, Checler F, Engel WK, Askanas V. Amyloid- β 42 is preferentially deposited in muscle biopsies of patients with sporadic inclusion-body myositis (s-IBM). *Neurology* 2003;60:333–334.
98. Vattemi G, Engel WK, McFerrin J, Askanas V. Cystatin C colocalizes with amyloid- β and co-immunoprecipitates with amyloid- β precursor protein in sporadic inclusion-body myositis muscle. *J Neurochem* 2003;85:1539–1546. [PubMed: 12787072]
99. Vattemi G, Engel WK, McFerrin J, Askanas V. Endoplasmic reticulum stress and unfolded protein response in inclusion-body myositis muscle. *Am J Pathol* 2004;164:1–7. [PubMed: 14695312]
100. Vattemi G, Engel WK, McFerrin J, Buxbaum JD, Pastorino L, Askanas V. Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis. *Lancet* 2001;358:1962–1964. [PubMed: 11747923]
101. Vattemi G, Engel WK, McFerrin J, Pastorino L, Buxbaum JD, Askanas V. BACE1 and BACE2 in pathologic and normal human muscle. *Exp Neurol* 2003;179:150–158. [PubMed: 12618121]
102. Vattemi G, Kefi M, Engel WK, Askanas V. Nicastrin, a novel protein participating in amyloid- β production, is overexpressed in sporadic inclusion-body myositis muscle. *Neurology* 2003;60:A315.
103. Vetrivel KS, Thinakaran G. Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. *Neurology* 2006;66:S69–73. [PubMed: 16432149]
104. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. *Annu Rev Biochem* 1999;68:1015–1068. [PubMed: 10872471]
105. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. *J Neurochem* 2007;101:1172–84. [PubMed: 17286590]
106. Wang H-Q, Takahashi R. Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's Disease. *Antioxid Redox Signal* 2006;9:553–561. [PubMed: 17465880]

107. Wojcik S, Engel WK, McFerrin J, Askanas V. Myostatin is increased and complexes with amyloid-beta within sporadic inclusion-body myositis muscle fibers. *Acta Neuropathol* 2005;110:173–77. [PubMed: 15983828]
108. Wojcik S, Engel WK, McFerrin J, Paciello O, Askanas V. AbetaPP-overexpression and proteasome inhibition increase α B-crystallin in cultured human muscle: relevance to inclusion-body myositis. *Neuromuscul Disord* 2006;16:839–844. [PubMed: 17056255]
109. Wojcik S, Engel WK, Yan R, McFerrin J, Askanas V. NOGO is increased and binds to BACE 1 in sporadic inclusion-body myositis and in A β PP-overexpressing cultured human muscle fibers. *Acta Neuropathol* 2007;114:517–526. [PubMed: 17764014]
110. Wojcik S, Nogalska A, McFerrin J, Engel WK, Oledzka G, Askanas V. Myostatin precursor protein is increased and associates with amyloid-beta precursor protein in inclusion-body myositis culture model. *Neuropathol Appl Neurobiol* 2007;33:238–242. [PubMed: 17359364]
111. Yamamoto H, Schoonjans K, Auwerx J. Sirtuin functions in health and disease. *Mol Endocrinol* 2007;21:1745–1755. [PubMed: 17456799]
112. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al. Modulation of NF- κ B-dependent transcription and cell survival by the SIRT1 deacetylase. *EMBO J* 2004;23:2369–2380. [PubMed: 15152190]
113. Sun Y, MacRae TH. The small heat shock proteins and their role in human disease. *FEBS J* 2005;272:2613–2627. [PubMed: 15943797]
114. Zhang K, Kaufman RJ. The unfolded protein response: a stress signaling pathway critical for health and disease. *Neurology* 2006;66:S102–109. [PubMed: 16432136]
115. Zhang K, Kaufman RJ. From endoplasmic-reticulum stress to the inflammatory response. *Nature* 2008;454:455–462. [PubMed: 18650916]

Fig. 1. Light-microscopic diagnostic features of the s-IBM muscle biopsy

a,b - Engel Trichrome staining demonstrating vacuolated and atrophic muscle fibers, and mononuclear-cell inflammation. **c** - Congo-red staining, visualized through Texas-red filters and epifluorescence illumination, shows various-sized amyloid deposits within two abnormal muscle fibers. **d** - Diagnostic inclusions within muscle fibers identified by staining with SMI-31 antibody, which identifies phosphorylated tau. **e** - Typical muscle-fiber inclusions identified with anti-ubiquitin antibody. **f** - Various-sized amyloid- β immunoreactive inclusions within a muscle fiber. **a,b** $\times 1250$; **c-f** $\times 2100$.

Fig. 2. Characteristic electronmicroscopic abnormalities of s-IBM muscle fibers

a, b - Several paired helical filaments (PHFs), in transmission electron microscopy. **c** - Cluster of PHFs immuno-stained with AT8 antibody, which recognizes phosphorylated tau, and processed for horseradish immunoperoxidase staining demonstrates dark reaction-product covering PHFs exclusively, while the adjacent portion of the myofiber is not immunostained. **d** - Cluster of PHFs immuno-stained with SMI-31 antibody, which recognizes phosphorylated tau, and processed for gold-immuno-electron microscopy; this demonstrates that gold particles associate only with PHFs, while the adjacent portion of the myofiber is not immunostained. **e, f** - Gold-immuno-electron microscopy of A β illustrates its localization on amorphous and floccular material, and on thin 6-10nm amyloid-like fibrils (arrows). **a,b,e,f** $\times 120,000$; **c,d** $\times 60,000$.

Fig. 3. Amyloid-β 42 (Aβ42) and Congo-red positivities in s-IBM muscle fibers
a - imunofluorescence and **c** - gold-immuno-electronmicroscopy of Aβ42 -- stained with an antibody specifically recognizing Aβ42 (ref.97 here) -- illustrate that Aβ42 aggregates in **a** correspond to 6-10 nm amyloid-like filaments in **c**. **b** - Cong-red staining of a transverse parallel, but not closely adjacent, section of the same fiber as in (**a**), demonstrating several amyloid inclusions. **a, b** ×2100; **c** ×2100.

Fig. 4. Proposed pathologic regulation of myostatin-precursor protein (MSTN-PP)/ myostatin (MSTN) in s-IBM muscle fibers

Endoplasmic reticulum (ER) stress induces MSTN-PP transcription through activation of NF-κB. Increased MSTN then leads to muscle fiber atrophy. Furthermore, increased AβPP/Aβ, which also causes proteasome inhibition, binds to MSTN-PP/MSTN and both accumulate in the form of probably-insoluble aggregates.

Fig. 5. Proposed adverse effects of decreased SIRT1 deacetylase activity in s-IBM muscle fibers
 Decreased deacetylase activity of SIRT1 activates NF-κB by increasing its acetylation (NF-κB-Ac). This leads to increased myostatin, and other detrimental consequences. Decreased SIRT1 activity also increases AβPP and Aβ, resulting in their known detrimental effects in s-IBM muscle fibers, as detailed in the text. Decreased SIRT1 activity might also inhibit autophagy, contributing to the accumulation of multiprotein aggregates.